Genzyme Europe

Pegcetacoplan (EMPAVELI) is a subcutaneous complement inhibitor developed by Apellis Europe B.V. for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder characterized by complement-mediated hemolysis. The program is currently in Phase 3 development with an active status and latest milestone dated April 6, 2026. Pegcetacoplan has already achieved regulatory approval in multiple jurisdictions: the European Union granted marketing authorization on December 16, 2024 and May 7, 2026 under two separate EMA product numbers (EMEA/H/C/005553 and EMEA/H/C/005954), the United States approved the drug under two NDAs (NDA215014 and NDA217171), and Australia approved it on December 1, 2022 and December 1, 2025 with multiple PBS codes indicating reimbursement coverage. The drug is classified as an antineoplastic and immunomodulating agent (ATC L04) and is administered via subcutaneous injection. Apellis' strategy centers on addressing the unmet medical need in PNH through complement pathway inhibition, leveraging the subcutaneous route for patient convenience. The presence of two distinct EMA authorizations and multiple PBS listings suggests either label expansions, formulation variants, or sequential approvals across different indications or patient populations within the rare disease space.

Paroxysmal nocturnal hemoglobinuria is a rare, life-threatening blood disorder with significant unmet medical need despite existing therapies. PNH patients suffer from complement-mediated hemolysis, thrombosis, and organ dysfunction, requiring effective long-term management. The approval of pegcetacoplan represents an important therapeutic option in the complement inhibition space, which has become increasingly competitive following the success of earlier C5 inhibitors and newer proximal pathway inhibitors. The subcutaneous administration route offers practical advantages over intravenous alternatives, potentially improving patient adherence and quality of life in this chronically managed rare disease population. Market relevance is underscored by the multiple regulatory approvals across major markets (EU, US, Australia) and the presence of multiple PBS codes in Australia indicating differentiated reimbursement pathways, suggesting commercial significance and payer recognition. The competitive landscape includes other immunomodulatory agents, though the specific mechanism and clinical positioning of pegcetacoplan relative to these competitors requires further clinical evidence. The Phase 3 status with an active milestone in April 2026 indicates ongoing clinical development, potentially supporting label expansions or additional indications beyond the initial approved use.

Drug Class: Complement inhibitor, classified as an antineoplastic and immunomodulating agent (ATC L04).

Modality: Small molecule.

Route of Administration: Subcutaneous injection.

Mechanism of Action: Not yet disclosed in available facts.

Target: Not yet disclosed in available facts.

Brand Name: EMPAVELI.

Related Therapies: Pegcetacoplan operates within the complement inhibition therapeutic class for rare hematologic disorders. The competitive landscape includes other immunomodulatory agents such as RAPAMUNE (Pfizer), LENALIDE (Bristol-Myers Squibb), POMALIDOMIDE SANDOZ (Lacuna Pharma), and RILONACEPT FGK (Regeneron), though the specific therapeutic positioning and comparative efficacy of pegcetacoplan relative to these agents is not detailed in available facts.

First Approval: European Union approval on December 16, 2024 (EMEA/H/C/005954) and May 7, 2026 (EMEA/H/C/005553); United States approval under NDA215014 and NDA217171; Australia approval December 1, 2022 and December 1, 2025.

Patent Status: Not yet disclosed.

United States: Pegcetacoplan approved under two NDAs: NDA215014 and NDA217171. Specific approval dates not yet disclosed.

European Union: Marketing authorization granted under two distinct EMA product numbers:

• EMEA/H/C/005954 — authorized December 16, 2024
• EMEA/H/C/005553 — authorized May 7, 2026

Marketing authorization holders: Apellis Europe B.V. and Swedish Orphan Biovitrum AB (publ).

Australia: Approved by the Therapeutic Goods Administration with multiple PBS listings:

• Initial approval: December 1, 2022 (PBS code 13175K)
• Additional listings: December 1, 2025 (PBS codes 13180Q, 13185Y, 13191G, 13196M, 13197N, 15117P, 15127E)

Sponsor names listed: Swedish Orphan Biovitrum Pty Ltd.

Japan (PMDA): Regulatory status not yet disclosed.

China (NMPA): Regulatory status not yet disclosed.

Strategic Positioning: Apellis' dual EMA authorizations (December 2024 and May 2026) and multiple Australian PBS listings suggest a phased regulatory strategy, potentially reflecting label expansions, distinct patient populations, or formulation variants within PNH. The Phase 3 status with an active milestone in April 2026 indicates ongoing clinical development despite prior approvals, suggesting either additional indications or expanded use cases under investigation.

Commercial Implications: The multiple PBS codes in Australia (seven distinct listings) indicate differentiated reimbursement pathways, suggesting payer recognition of distinct clinical scenarios or dosing regimens. This granular reimbursement structure may reflect disease severity stratification or patient population segmentation, enhancing market access and revenue potential.

Competitive Dynamics: The subcutaneous route offers practical advantages over intravenous complement inhibitors, potentially capturing patient preference and improving adherence in chronic rare disease management. However, direct comparative efficacy and safety data against other complement inhibitors are not disclosed.

Future Catalysts: Expected next milestones and clinical trial results from NCT03531255 and NCT03593200 remain undisclosed. Completion of Phase 3 activities and potential label expansions represent key value drivers. Regulatory submissions in Japan (PMDA) and China (NMPA) would expand market access in high-value Asian markets.

Patent and Exclusivity: Patent status and exclusivity periods are not yet disclosed, limiting assessment of long-term market protection.